Faculty Profile, National Health Research Institutes, Taiwan

Faculty Profiles

Yi-Ming Arthur Chen, M.D., M.S., Sc.D.

Adjunct Investigator
Vaccine Research and Development Center


  • Sc.D., Department of Cancer Biology, Harvard School of Public Health, Boston, MA, USA, 1986-1990
  • M.S., Institute of Microbiology and Immunology, National Yang-Ming University, Taiwan, 1982-1984
  • M.D., National Yang-Ming University, Taiwan, 1975-1982


  • Professor, Institute of Microbiology and Immunology, Natl Yang-Ming University (2007-present)
  • Professor, Institute of Public Health, Natl Yang-Ming University (1998-2007)
  • Visiting Scientist, HIV Drug Resistance Program, NCI, USA (2002-2003)
  • Asso. Res. Member, Institute of Biomedical Sciences, Academia Sinica (1992-1994)
  • Associate Prof, Institute of Public Health, Natl Yang-Ming University (1992-1998)
  • Visiting Scientist, Lab of Molecular Oncology, National Cancer Institute USA (1990-1992)
  • Lecturer, Department of Microbiol & Immunol, Natl Yang-Ming University (1986)
  • Aviation Doctor, Air-force General Hospital, Natl Yang-Ming University (Military services) (1984-1986)
  • Teaching Assistant, Dept of Microbiol & Immunol, Natl Yang-Ming University (1982-1984)


    Dr. Chen’s researches focus on the following two areas: a.) Use both transgenic and gene-knockout mouse models to study the function of GNMT in liver tumorigenesis and brain diseases; and b.) Molecular epidemiology and virology of HIV-1, HCV, HHV-8 and influenza virus in Taiwan.


    Dr. Chen devoted himself in the prevention and research of HIV-1/AIDS and cancer. In 1990, with his mentor-Professor Max Essex, he published two articles in Lancet describing the type-specific antigens for the distinction between human T-cell leukemia viruses type I and type II and early antibody reactivity of new HTLV-I seroconverters. After he came back to Taiwan, he established the first AIDS research center in 1998. Since 2003, his expertise in the molecular epidemiology and phylogenetic analysis has resulted in the detailed description of the transmission pathways of both SARS coronavirus and HIV-1 circulating recombinant form 07_BC in Taiwan.
    Dr. Chen started to study liver cancer when he was a master student at the National Yang-Ming University (NYMU) in 1983. He found that glycine N-methyltransferase (GNMT) was down-regulated in most of the adult liver cancer cells (Int J Cancer 1998). Subsequently, he cloned the human GNMT genome (Genomics 2000) and characterized the genetic polymorphism and identified its liver cancer-associated genotypes (Cancer Res 2003). After nearly 5 years’ effort, he developed a GNMT- gene-knockout mouse model (Hepatology 2007) which is very useful for the studies of the pathogenesis and drug development.


  • Scholarships from the National Science of Council of ROC for short-term training (2003)
  • Who’s Who in Medicine and Healthcare, 2002-2003
  • Young Investigator Award, First Joint Annual Conference of the Society of Oncology, Taiwan, 1996
  • Candidate for the International Prince Mahidol Award from Thailand, nominated by the Department of Health, Executive Yuan, R.O.C., 1994
  • Education and Culture Award, Significant Contribution to the Scientific Education for the Public, from the Ministry of Education, Taiwan, 1993
  • Scholarship from the Fogarty International Center, National Institutes of Health, Program of International Training Grants 1989-92
  • Scholarship from the Ministry of Education to study abroad, Taiwan, R.O.C., 1986-89
  • Scholarship from Society of Microbiology of ROC, Yen Shi-Chung Award, 1983.


    1.Liu SP, Li YS, Chen YJ, Chiang EP, Li AFY, Lee YH, Tsai TF, Hsiao M, Huang CF, Chen YM.* Glycine N-methyltransferase-/- mice develop chronic hepatitis and glycogen storage disease in liver. Hepatol 2007; 46: 1413-1425.

    2.Chen CY, Ping YH, Lee HC, Chen KH, Lee YM, Lian DC, Jap TS, Lin CH, Kao LS, Chen YM.* ORF8a of the severe acute respiratory syndrome coronavirus not only promotes viral replication but also induces apoptosis. J Inf Dis, 2007; 196: 405-415.

    3.Lin YT, Lan YC, Chen YJ, Liu TT, Yang JY, Wong WW, Wang CT, Chen YM.* Molecular epidemiology and full-length genomic analysis of HIV-1 circulating recombinant form 07_BC strains from injecting drug users in Taiwan. J Infect Dis, 195: 1283-1293, 2007.

    4.Huang YC, Lee CM, Shih YP, Chung MY, Chang YH, Huang JSW, Ho MTD, Pan CC, Wu TL, Hsu JM, Yang S, Lin MW, Chen YM.* Characterization of the haplotypes, loss of heterozygosity and expression levels of glycine N-methyltransferase gene in prostate cancer. Clin Cancer Res, 13: 1412-1420, 2007.

    5.Chen YM* and Kuo HS. HIV-1 in Taiwan. Lancet, 369: 623-625, 2007.

    6.Shih YP, Chen CY, Liu SJ, Chen KH, Lee YM, Chao YC, Chen YM.* Identification of the Epitopes Responsible for Neutralizing Antibody and DC-SIGN Binding on the Spike Glycoprotein of the Severe Acute Respiratory Syndrome Coronavirus. J Virol, 80: 10315-10324, 2006.

    7.Chen YM*, Lan YC, Lai SF, Yang JY, Tsai SF, Kuo HS. HIV-1 CRF07_BC infections, injecting drug users, Taiwan. Emerg Infect Dis, 12: 703-705, 2006.


  • Glycine N-methyltransferase monoclonal antibodies and methods of use therefore. Patent number: 0040101913. (Duration: 2005-2025)
  • ROC Patent: Detection and Correction of Abnormalities of Cells having Decreased Levels of Glycine N-methyltransferase. Patent number: 086114505 (Duration: Oct. 4, 1997-Oct. 4, 2017)
  • United States Patent: Detection and Correction of Abnormalities of Cells having Decreased Levels of Glycine N-methyltransferase. Patent number: 5994093 (Duration: Nov. 30, 1999-Nov. 30, 2019)